Imclone LLC
Records under this name other than the patents Imclone LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,128,929 | ANTIBODIES AGAINST PDGFRa Formerly held In force · High confidence | In force | High confidence | |
| US 8,574,578 | Antibodies against PDGFRα to inhibit tumor growth Term ended Term ended Jun 19, 2026 · From the USPTO record | Term ended | Term ended Jun 19, 2026 | From the USPTO record |
| US 7,498,414 | Human antibodies specific to KDR and uses thereof Term ended Term ended Jan 31, 2026 · From the USPTO record | Term ended | Term ended Jan 31, 2026 | From the USPTO record |
| US 8,263,079 | Antibodies against CSF-1R Lapsed on the fee record Ended Sep 11, 2024 · From the USPTO record | Lapsed on the fee record | Ended Sep 11, 2024 | From the USPTO record |
| US 8,057,791 | Human antibodies specific to KDR and uses thereof Term ended Term ended Dec 7, 2023 · From the USPTO record | Term ended | Term ended Dec 7, 2023 | From the USPTO record |
| US 8,425,911 | Methods of treating secondary bone tumors with antibodies against PDGFR alpha Lapsed on the fee record Ended Apr 23, 2021 · From the USPTO record | Lapsed on the fee record | Ended Apr 23, 2021 | From the USPTO record |
| US 9,375,488 | Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatment Formerly held Lapsed on the fee record Ended Jun 28, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jun 28, 2020 | From the USPTO record |
| US 8,147,834 | Anti-TGF-beta receptor II antibodies Lapsed on the fee record Ended Apr 3, 2020 · From the USPTO record | Lapsed on the fee record | Ended Apr 3, 2020 | From the USPTO record |
| US 8,143,025 | Antibodies against vascular endothelial growth factor receptor-1 Lapsed on the fee record Ended Mar 27, 2020 · From the USPTO record | Lapsed on the fee record | Ended Mar 27, 2020 | From the USPTO record |
| US 8,043,618 | Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment Lapsed on the fee record Ended Oct 25, 2019 · From the USPTO record | Lapsed on the fee record | Ended Oct 25, 2019 | From the USPTO record |